Well the big question about the Galderma non-disclosure is not about the actual contract but the pattern of behaviour it exposed - that made QIN uninvestible.
Future value is still predicated on QIN developing a huge new market for their product when they couldn't even sell their tiny harvest without pulling forward demand from an existing customer at a discount.
$100m won't fix it, I don't think $300m would either.
QIN Price at posting:
29.5¢ Sentiment: Sell Disclosure: Not Held
